At LogiPharma USA 2026, Cold Chain Technologies' TJ Rizzo explains how gaps in end-to-end cold chain expertise create risk for advanced therapies.
News|Articles|September 15, 2026
Consistency as a Competitive Advantage in a Changing Market
Author(s)CoverMyMeds
This infographic leverages IQVIA data and analytics to explore how one pharmaceutical brand used CoverMyMeds’ prior authorization strategies to achieve an observed average 22 percentage point improvement in claim approval rates—growing and defending market share in a highly managed class.
Related to this article
Octapharma USA's Kerem Tokel explains how tariffs and DSCSA are affecting how stolen pharma loads are resold, and why partner SOPs matter.
At LogiPharma USA 2026, Mark Talens explains where pharma gains the most from shared distribution visibility.
In this week's Pharma Pulse, PhRMA sues to block CMS's GLOBE pricing model, WFS opens a temperature-controlled cargo terminal in Lyon and Bayer commits $2.2 billion to a new Ohio manufacturing site.
Freehand CEO Nitin Jayakrishnan explains why pharma manufacturers are trading long-term plans for operating models built to sense and pivot.
PhRMA's lawsuit argues CMS overstepped its demonstration authority by tying Medicare Part B rebates to international prices.
At LogiPharma USA 2026, Swisslog's Garrett Freeman explains how onshoring, geopolitical risk and a shifting product mix are driving supply chain automation.
At LogiPharma USA 2026, quality leaders explained why connected data, risk-based prioritization, and human accountability must come before AI in supply chain compliance.
Trending on Pharmaceutical Commerce
1
Why Securing Pharma Freight Starts With Broker and Carrier SOPs
2
LogiPharma USA 2026: Where Cold Chain Expertise Gaps Become Product Risk
3
Supply Chain Visibility Needs Context Before AI, Says PAXAFE’s Mark Talens
4
Pharma Pulse: PhRMA Sues to Block GLOBE Model and Bayer's $2.2B Ohio Site
5